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for Clonazepam and 181 for Fluoxetine and Imipramine. The
incremental cost-effectiveness analysis showed that the cost of an
extra unit of effectiveness was $32.2 when changing from Alpra-
zolam to Clonazepam, while the two other alternatives (Fluox-
etine and Imipramine) were dominated. Sensitivity analysis
conﬁrmed the direction and strength of our results. Conﬁdence
interval at 95% of the ICER was calculated by the ellipse method
and it showed that Alprazolam was dominant in 87% of the
cases. Acceptability curve described Alprazolam as the best
option with a willingness to pay threshold of $32.2. CONCLU-
SIONS: The best cost-effective alternative was Alprazolam fol-
lowed by Clonazepam. This results are relevant for the IMSS
because anxiety disorders cause work leaves and hospitalisa-
tions, and reduction in quality of life.
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OBJECTIVES: To assess the health and cost burdens of patients
with generalized anxiety disorder (GAD) and other anxiety dis-
orders, including their comorbidities, direct and indirect costs.
METHODS: The 1999–2003 MarketScan® claims databases of
over three million individuals (annually) were used to identify
patients with a diagnosis of GAD, other anxiety disorders (panic
disorder, phobias, post traumatic stress disorder, unspeciﬁed
anxiety state), and demographically-matched controls. Presence
of comorbidities, utilization, expenditures, absence and short-
term disability (STD) were summarized over a 12-month study
period. RESULTS: The prevalence of the following conditions
were signiﬁcantly (p < 0.001) higher among the 13,836 GAD
subjects and 31,882 other anxiety patients compared to the
89,971 controls: gastrointestinal disorders (19% GAD, 22%
other anxiety, 12% controls), genitourinary disorders (40%
GAD and other anxiety, 32% controls), cardiovascular disease
(10% GAD, 11% other anxiety, 7% controls), and chronic pain
(40% GAD, 44% other anxiety, 20% controls). Mean costs for
anxiety patients were twice as high as for controls ($6295 GAD,
$6800 other anxiety, $3156 controls, p < 0.001). These differ-
ences were driven by signiﬁcantly higher rates of ofﬁce visits and
prescription drug use among anxiety patients. Mental health
costs for GAD patients ($2031) or other anxiety patients ($2005)
did not account for all of the discrepancy. Among the subset of
patients with productivity data, anxiety patients had signiﬁcantly
higher indirect costs due to STD days ($2253 GAD, $3255 other
anxiety, $934 controls, p < 0.001). CONCLUSION: Patients
with GAD and other anxiety disorders have signiﬁcantly higher
costs compared to patients without these conditions. The direct
and indirect costs of anxiety result from mental health treatment
and treatments for physical comorbidities.
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OBJECTIVES: To examine the determinants of time-to-
permanent nursing home admission among people aged 65 years
and over in the United States. METHODS: This study used data
from four waves of the Health Retirement Study (HRS) and
Assets and Health Dynamics among the Oldest Old surveys
(AHEAD) collected from 1995 to 2002. The dependent variable
was time-to-permanent nursing home admission, deﬁned as the
months from baseline survey in 1995 to the ﬁrst nursing home
stay of three or more months. Independent variables were mea-
sured at the baseline and included age, gender, race, education,
marital status, living arrangements, income, homeownership,
Medicaid, physical function (ADL/IADL), cognitive level, per-
ceived health status and certain chronic illnesses such as stroke,
psychiatric problems, fall and incontinence. RESULTS: In the
ﬁnal multivariable Cox model, older age (Hazard Ratio [HR],
1.11; 95% CI, 1.09–1.24), persons with psychiatric problems
(HR, 1.49; 95% CI, 1.19–1.87) and worse health were found 
to increase the risk of permanent nursing home admission
whereas being African American compared to white (HR, 0.85;
95% CI, 0.56–0.95) and persons with less cognitive impairment
(HR, 0.95; 95% CI, 0.91–0.99) had decreased risk. The inter-
action terms between time and living alone and IADL were 
signiﬁcant and less than one, which means the negative impacts
of living alone and worse IADL were decreasing over time.
Gender, education, marital status, income, homeownership,
Medicaid, ADL, stroke, fall and incontinence were not signiﬁ-
cant. CONCLUSION: Older age, psychiatric problems and
worse perceived health are the risk factors for permanent nursing
home admission. Living alone and worse IADL also increase the
risk of nursing home admission, however, the negative impacts
appear to ameliorate over time. The differential effects of ADL
and IADL on nursing home admission warrant more future
research.
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OBJECTIVES: This study assessed the effect of treatment with
venlafaxine extended release (XR), paroxetine and placebo on
health related work productivity among panic disorder patients.
METHODS: In a multicenter, double-blind trial, patients with
DSM-IV panic disorder were randomly assigned to ﬁxed-dose
(75mg/day or 225mg/day) venlafaxine XR, paroxetine 
(40mg/day), or placebo for a maximum of 12-weeks. Secondary
analyses focused on health-related work productivity impair-
ments as measured by the Work Limitations Questionnaire
(WLQ). WLQ has 25 items in four limitation dimensions (time,
physical, mental-interpersonal, and output demands). Treat-
ment-related improvements at ﬁnal-on-therapy (FOT) and week
12 were compared using analysis of covariance adjusting for
baseline impairment score and center. RESULTS: Venlafaxine
XR 225mg was associated with signiﬁcantly greater improve-
ment from baseline, relative to placebo, on all subscales of WLQ
(P < 0.005) except physical demands. At the FOT assessment,
venlafaxine XR 75mg showed signiﬁcant improvement com-
pared with placebo in time management (P < 0.05), marginally
signiﬁcant improvement in mental/interpersonal demands (P =
0.059) and output demands (P = 0.054), and no signiﬁcance 
for physical demands. Paroxetine failed to show signiﬁcant
improvement relative to placebo on all WLQ subscales in the
FOT assessment. CONCLUSION: Venlafaxine reduced work
impairment compared to placebo. Paroxetine did not separate
from placebo.
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